The relationship between obstructive sleep apnoea and quality of life in women with polycystic ovary syndrome: a cross-sectional study.

obesity obstructive sleep apnoea polycystic ovary syndrome quality of life

Journal

Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143

Informations de publication

Date de publication:
2020
Historique:
received: 21 04 2019
accepted: 21 01 2020
entrez: 5 3 2020
pubmed: 5 3 2020
medline: 5 3 2020
Statut: epublish

Résumé

Obstructive sleep apnoea (OSA) and polycystic ovary syndrome (PCOS) are associated with significant comorbidities and commonly coexist. The primary aim of this study was to examine the relationship between OSA and quality of life (QoL) in women with PCOS. We conducted an observational cross-sectional study. PCOS was diagnosed according to the Rotterdam criteria. Women with increased risk of OSA, based on the Berlin questionnaire or the Epworth Sleepiness Scale (ESS), had home-based polysomnography performed (ALICE PDx). Participants were divided into two groups: (a) PCOS only: women with normal ESS and low-risk Berlin questionnaire (no sleep studies performed), or women with normal sleep studies [oxygen desaturation index (ODI) < 5 events/hour]; and (b) PCOS+OSA: women with PCOS and OSA ODI ⩾ 5. QoL was assessed using the World Health Organization QoL questionnaire (WHOQOL-BREF) and the PCOS health-related quality of life questionnaire (PCOSQ). A total of 39 women were included; age (mean ± SD) was 32.2 ± 8.9 years, weight 92.5 ± 23.7 kg and body mass index (BMI) 34.1 ± 7.9 kg/m OSA is highly prevalent and is associated with impaired QoL and worse metabolic profile in women with PCOS. Interventional studies are needed to examine the impact of OSA in women with PCOS. NCT03065322.

Sections du résumé

BACKGROUND BACKGROUND
Obstructive sleep apnoea (OSA) and polycystic ovary syndrome (PCOS) are associated with significant comorbidities and commonly coexist. The primary aim of this study was to examine the relationship between OSA and quality of life (QoL) in women with PCOS.
METHODS METHODS
We conducted an observational cross-sectional study. PCOS was diagnosed according to the Rotterdam criteria. Women with increased risk of OSA, based on the Berlin questionnaire or the Epworth Sleepiness Scale (ESS), had home-based polysomnography performed (ALICE PDx). Participants were divided into two groups: (a) PCOS only: women with normal ESS and low-risk Berlin questionnaire (no sleep studies performed), or women with normal sleep studies [oxygen desaturation index (ODI) < 5 events/hour]; and (b) PCOS+OSA: women with PCOS and OSA ODI ⩾ 5. QoL was assessed using the World Health Organization QoL questionnaire (WHOQOL-BREF) and the PCOS health-related quality of life questionnaire (PCOSQ).
RESULTS RESULTS
A total of 39 women were included; age (mean ± SD) was 32.2 ± 8.9 years, weight 92.5 ± 23.7 kg and body mass index (BMI) 34.1 ± 7.9 kg/m
CONCLUSIONS CONCLUSIONS
OSA is highly prevalent and is associated with impaired QoL and worse metabolic profile in women with PCOS. Interventional studies are needed to examine the impact of OSA in women with PCOS.
CLINICALTRIALSGOV IDENTIFIER BACKGROUND
NCT03065322.

Identifiants

pubmed: 32128106
doi: 10.1177/2042018820906689
pii: 10.1177_2042018820906689
pmc: PMC7036513
doi:

Banques de données

ClinicalTrials.gov
['NCT03065322']

Types de publication

Journal Article

Langues

eng

Pagination

2042018820906689

Informations de copyright

© The Author(s), 2020.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declare the following conflicts of interest: AAT is a Clinician Scientist supported by the National Institute for Health Research (NIHR). NIHR Clinical Lectureship supported HK. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Références

Obes Rev. 2017 Apr;18(4):460-475
pubmed: 28117952
Fertil Steril. 2004 Jan;81(1):19-25
pubmed: 14711538
J Clin Endocrinol Metab. 1998 Jun;83(6):1976-87
pubmed: 9626128
Sleep. 2015 Mar 01;38(3):351-60
pubmed: 25581913
Sleep. 2015 Dec 01;38(12):1995-2003
pubmed: 26237774
Fertil Steril. 2011 Aug;96(2):452-8
pubmed: 21703610
Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30
pubmed: 7258262
J Clin Endocrinol Metab. 2011 Feb;96(2):365-74
pubmed: 21123449
Sleep. 2007 May;30(5):619-24
pubmed: 17552377
Eur J Endocrinol. 2019 Apr;180(4):265-272
pubmed: 30763274
Sleep. 2005 Apr;28(4):449-56
pubmed: 16171289
J Am Assoc Nurse Pract. 2013 May;25(5):223-33
pubmed: 24170564
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1259-66
pubmed: 23725615
Sleep. 2018 Jul 1;41(7):
pubmed: 29722890
Anesth Analg. 2012 May;114(5):993-1000
pubmed: 22366847
J Clin Sleep Med. 2017 May 15;13(5):665-666
pubmed: 28416048
Nat Sci Sleep. 2018 Feb 01;10:45-64
pubmed: 29440941
Health Expect. 2012 Mar;15(1):49-62
pubmed: 21281412
Sleep Breath. 2019 May 20;:
pubmed: 31111411
Am J Respir Crit Care Med. 2003 May 1;167(9):1186-92
pubmed: 12531779
Clin Endocrinol (Oxf). 2017 Oct;87(4):313-319
pubmed: 28640938
Sleep Breath. 2003 Mar;7(1):25-9
pubmed: 12712394
Hum Reprod Update. 2010 Jul-Aug;16(4):347-63
pubmed: 20159883
Clin Endocrinol (Oxf). 2007 Apr;66(4):513-7
pubmed: 17371468
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Sleep. 2012 Jan 01;35(1):89-96
pubmed: 22215922
Sleep Med. 2017 Aug;36:165-169
pubmed: 28599952
Ann Intern Med. 1999 Oct 5;131(7):485-91
pubmed: 10507956
J Psychosom Res. 1997 Jan;42(1):17-41
pubmed: 9055211
Sleep Med Rev. 2018 Aug;40:4-16
pubmed: 28890168

Auteurs

Hassan Kahal (H)

Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK.

Abd A Tahrani (AA)

Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Ioannis Kyrou (I)

Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK.

Georgios K Dimitriadis (GK)

Department of Endocrinology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK.

Peter K Kimani (PK)

Statistics and Epidemiology, Warwick Medical School, University of Warwick, Coventry, UK.

Thomas M Barber (TM)

Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Matthew Nicholls (M)

Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Asad Ali (A)

Department of Respiratory Medicine, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.

Martin O Weickert (MO)

Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK.

Harpal S Randeva (HS)

Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM) and Human Metabolism Research Unit (HMRU), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, UK.

Classifications MeSH